Cogent Biosciences Inc
Open
33.38 0.27
Overview
Share price change
24h
Min
32.76
Max
33.56
Income | 947K -96M |
|---|---|
EPS | -0.52 |
Employees | 258 |
EBITDA | 537K -94M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +62.06% upside |
Next Earnings | 2 lis 2026 |
|---|
Market Cap | -608M 6B |
|---|---|
Previous open | 33.11 |
Previous close | 33.38 |
Cogent Biosciences Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Cogent Biosciences Inc Forecast
Price Target
By TipRanks
62.06% upside
12 Months Forecast
Average 54.143 USD 62.06%
High 62 USD
Low 45 USD
Based on 8 Wall Street analysts offering 12 month price targets forCogent Biosciences Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
